CoChat

Association of plasma biomarkers, p‐tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long‐term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years

Open access
Stocker, Hannah, Beyer, Léon, Perna, Laura, Rujescu, Dan, Holleczek, Bernd, Beyreuther, Konrad, Stockmann, Julia, Schöttker, Ben, Gerwert, Klaus, Brenner, Hermann · 2023 · Alzheimer's & Dementia
Cited by 98

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Introduction: Blood biomarkers for Alzheimer's disease (AD) are the future of AD risk assessment. The aim of this study was to determine the association between plasma‐measured phosphorylated tau (p‐tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) levels and risk of clinical AD incidence with consideration to the impact of cardiovascular health. Methods: Within a community‐based cohort, biomarker levels were measured at baseline using single molecule array technology in 768 participants (aged 50–75) followed over 17 years. Associations among biomarkers and AD, vascular dementia, and mixed dementia incidence were assessed. Results: GFAP was associated with clinical AD incidence even more than a decade before diagnosis (9–17 years), while p‐tau181 and NfL were associated with more intermediate AD risk (within 9 years). Significant interaction was detected between cardiovascular health and p‐tau181/NfL. Discussion: GFAP may be an early AD biomarker increasing before p‐tau181 and NfL and the effect modifying role of cardiovascular health should be considered in biomarker risk stratification.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/alz.12614

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 98

Metadata

Authors
Stocker, H., Beyer, L., Perna, L., Rujescu, D., Holleczek, B., Beyreuther, K., Stockmann, J., Schöttker, B., Gerwert, K., & Brenner, H.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2022-03-02
Volume
19
Issue
1
Pages
25-35
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W4214824885
Cited by
98
References
19
FWCI
12.80
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of plasma biomarkers, p‐tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long‐term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years. https://app.cochat.ai/papers/10.1002/alz.12614
The paper
Stocker, H., Beyer, L., Perna, L., Rujescu, D., Holleczek, B., Beyreuther, K., Stockmann, J., Schöttker, B., Gerwert, K., & Brenner, H. (2023). Association of plasma biomarkers, p‐tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long‐term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years. Alzheimer's & Dementia. https://doi.org/10.1002/alz.12614

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.